Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IPOD vs ABSI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IPOD Captures Overall Composite Edge (58.0 HOLD vs 41.3 SELL), While ABSI Leads 3–2 on Growth & Valuation Pillars

IPOD Overall Winner 6-Pillar Tally: IPOD 2 – 3 ABSI (1 Tie) Matrix Metrics: IPOD 7 – 1 ABSI

As of Nov 16, 2026, IPOD (IPOD) captures the overall head-to-head institutional edge over Absci Corporation (ABSI) on higher Unified Composite conviction (58.0/100 HOLD vs. 41.3/100 SELL) after splitting the core matrix 7–1 (led by Valuation Multiples, Profitability & Quality), while ABSI wins 3–2 across the 6-pillar growth and valuation breakdown. IPOD trades at $10.42 (N/M Forward P/E, 0.0% operating margin) versus ABSI at $7.47 (N/M Forward P/E, -9108.3% operating margin).

  • Growth vs. Quality Trade-Off: IPOD earns the overall head-to-head edge with a stronger Unified Composite Score (58.0/100 HOLD vs. ABSI 41.3/100 SELL) and 0.00β · 2% Vol risk profile, whereas ABSI leads top-line expansion (-19.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: IPOD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ABSI is in a Breakdown options structure phase (RSI 38.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IPOD vs ABSI
IPOD US Equity Head-to-Head Winner
IPOD
Institutional Equity
$10.42
+0.39% 1D
Market Cap $210.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.00β · 2% Vol
Unified Composite Score
58.0 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
ABSI NASDAQ
Absci Corporation Common Stock
Services-Commercial Physical & Biological Research
$7.47
-11.54% 1D
Market Cap $1.5B
TTM Revenue $1.5M
Forward P/E N/M
Beta / 30D Vol 3.34β · 128% Vol
Unified Composite Score
41.3 / 100 SELL
Tech 30.0 Fund 52.0 Flow 71.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.8 · SMA20: $9.94 · SMA50: $9.63

6-Pillar Scorecard Institutional Category Breakdown (IPOD 2 – 3 ABSI)

Columns: Metric · IPOD · ABSI
1. Valuation Multiples IPOD
Forward P/E N/M N/M
Trailing P/E 39.9x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ABSI
Revenue Growth (YoY) +0.0% -19.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $1.5M
Market Cap $210.0M $1.5B
3. Profitability & Quality IPOD
Gross Margin N/A N/A
Operating Margin 0.0% -9108.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) 0.0% -58.6%
4. Balance Sheet & Cash Flow ABSI
Cash Generation (TTM) N/A -$112M
Cash Flow Margin N/A N/A
Net Cash / Leverage 0.0% ROE $10M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABSI
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 169.1% (15th %ile)
Put/Call OI Skew N/A 0.57x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Shell Companies Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IPOD (7) vs ABSI (1)
Institutional Metric IPOD ABSI Criterion Row Edge
Market Capitalization
Scale
$210.0M $1.5B Larger Scale ABSI
Trailing P/E Ratio
Valuation
39.9x N/M Lower Multiple IPOD
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -19.6% Higher Growth IPOD
Operating Margin (TTM)
Profitability
0.0% -9108.3% Higher Margin IPOD
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
0.0% -58.6% Higher ROE IPOD
52-Week Range Position
Momentum
100% ($10–$10) 51% ($2–$13) Stronger Trend IPOD
Beta / 30D Volatility
Risk Regime
0.00β · 2% Vol 3.34β · 128% Vol Lower Realized Risk IPOD
Unified Institutional Score
Composite Signal
58.0 / 100 (HOLD) 41.3 / 100 (SELL) Higher Composite IPOD
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (0.0% ROE) -$112M ($10M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABSI +90.33 pp
IPOD: +0.97% · ABSI: +91.3%
3M Horizon ABSI +67.89 pp
IPOD: +2.16% · ABSI: +70.05%
6M Horizon ABSI +85.47 pp
IPOD: +1.76% · ABSI: +87.23%
1Y Horizon ABSI +85.47 pp
IPOD: +1.76% · ABSI: +87.23%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IPOD vs ABSI. Trailing 12-month operating profitability (IPOD 0.0% vs ABSI -9108.3%) and valuation multiples (IPOD N/M vs ABSI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IPOD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E0.0% · N/M
ABSI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.5M
Gross MarginN/A
Op. Margin-9108.3%
ROE / Fwd P/E-58.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IPOD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IPOD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABSI BREAKDOWN
97d in phase · OBV NEUTRAL
Current IV 169.1%
IV Percentile 15th %ile
Put/Call OI Skew 0.57x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABSI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IPOD Moat Profile Cyclical / Execution-Driven Positioning
Shell Companies Operator
Competes within the Shell Companies value chain with $210.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABSI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -9108.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IPOD vs ABSI Key Questions & Quantitative Answers

As of Nov 16, 2026, IPOD (IPOD) captures the overall head-to-head institutional edge over Absci Corporation (ABSI) on higher Unified Composite conviction (58.0/100 HOLD vs. 41.3/100 SELL) after splitting the core matrix 7–1 (led by Valuation Multiples, Profitability & Quality), while ABSI wins 3–2 across the 6-pillar growth and valuation breakdown. IPOD trades at $10.42 (N/M Forward P/E, 0.0% operating margin) versus ABSI at $7.47 (N/M Forward P/E, -9108.3% operating margin). Growth vs. Quality Trade-Off: IPOD earns the overall head-to-head edge with a stronger Unified Composite Score (58.0/100 HOLD vs. ABSI 41.3/100 SELL) and 0.00β · 2% Vol risk profile, whereas ABSI leads top-line expansion (-19.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: IPOD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ABSI is in a Breakdown options structure phase (RSI 38.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABSI leads the Growth & Scale pillar: IPOD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ABSI at -19.6% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (N/A gross margin, -9108.3% operating margin). On trailing 12-month operating scale, IPOD generates N/A in USD-normalized revenue versus $1.5M for ABSI. In operating R&D and SG&A reinvestment, IPOD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABSI.

IPOD screens cheaper on headline valuation multiples. IPOD trades at N/M Forward P/E, 39.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABSI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IPOD (0.0% ROE) versus ABSI (-58.6% ROE) capital efficiency.

In options market volatility and institutional positioning, IPOD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.00β · 2% Vol realized risk). By comparison, ABSI carries 169.1% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.34β · 128% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.